Article Text

PDF

Hypermethylation of FHIT predicts poor prognosis in NSCLC
  1. K Pavithran
  1. Consultant, Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India; drkpavithranhotmail.com

Statistics from Altmetric.com

DNA methylation of CpG sites in the promoter regions of tumour suppressor genes is a frequently acquired epigenetic event in the pathogenesis of many human cancers. The fragile histidine triad (FHIT) gene, located at chromosome 3p14.2, is a tumour suppressor gene. Methylation results in inactivation of these genes.

Maruyama and colleagues looked at the relationship between the methylation status of various genes and survival in patients with NSCLC. Surgically resected specimens from 124 patients (79 men) of median (range) age 69 (25–82) years with NSCLC were studied using PCR. The majority had early stage disease (59 stage I, 24 stage II). The frequency of methylation was highest for E-cadherin (52%) followed by RAS association domain family protein (41%), FHIT and adenomatous polyposis coli (38%), retinoic acid receptor beta and H-cadherin (27%), p16INK4A (20%), and O6-methylguanine-DNA-methyltransferase (0.8%). The 5 year survival rates of the patients with FHIT methylation-positive tumours was found to be significantly shorter (31.9% v 51.4%, p = 0.03), even in those patients with early stage disease (p = 0.007). However, the methylation status of other genes was not associated with any survival difference. In a multivariate analysis, FHIT methylation-positive status was found to be independently associated with poor survival (p = 0.046).

This study shows that methylation of FHIT is an independent factor associated with poor prognosis in patients with NSCLC.

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.